Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
Related deals
Nordian Capital has raised debt to acquire Wetac
Nordian Capital, a Netherlands-based private equity firm, has joined the shareholder base of Wetac Battery Company (Wetac), a leading supplier of batteries, battery systems and accessories for various applications and end markets. The financing was provided by OLB and will support Wetac’s strong growth ambitions.
Learn moreA group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.
Learn moreExpice has been acquired by Betronic
Betronic B.V. has raised acquisition financing provided by Rabobank to support the acquisition of Expice.
Learn more